Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$7.92 +0.1%	$8.02	$5.20 ▼ $10.67	$1.07B	1.15	1.33 million shs	1.05 million shs
EQRX EQRx	$2.34	$2.29	$1.58 ▼ $5.55	$1.14B	0.48	3.30 million shs	N/A
SAGE Sage Therapeutics	$9.13 +0.1%	$7.16	$4.62 ▼ $13.47	$571.73M	0.18	1.28 million shs	2.87 million shs
VERV Verve Therapeutics	$11.12 -2.3%	$5.34	$2.86 ▼ $11.41	$991.27M	1.67	2.36 million shs	13.05 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	+0.13%	-2.10%	-1.86%	-4.81%	+46.13%
EQRX EQRx	0.00%	0.00%	0.00%	0.00%	0.00%
SAGE Sage Therapeutics	+0.11%	+34.86%	+29.14%	+13.98%	-15.07%
VERV Verve Therapeutics	-2.28%	+74.02%	+154.46%	+100.72%	+118.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUPH Aurinia Pharmaceuticals	3.0796 of 5 stars	3.5	2.0	0.0	0.0	3.2	0.8	1.9
EQRX EQRx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	2.9501 of 5 stars	2.0	1.0	0.0	4.0	2.9	1.7	0.6
VERV Verve Therapeutics	2.9542 of 5 stars	4.2	1.0	0.0	0.0	2.9	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	3.00	Buy	$11.50	45.20% Upside
EQRX EQRx	0.00	N/A	N/A	N/A
SAGE Sage Therapeutics	2.00	Hold	$8.93	-2.15% Downside
VERV Verve Therapeutics	2.38	Hold	$14.75	32.64% Upside

Current Analyst Ratings Breakdown

Latest SAGE, EQRX, AUPH, and VERV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	VERV Verve Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$28.00 ➝ $11.00
6/18/2025	VERV Verve Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00
6/18/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$13.50
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/17/2025	VERV Verve Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Market Perform
6/17/2025	VERV Verve Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$39.00 ➝ $13.00
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/25/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$235.13M	4.55	$0.31 per share	25.68	$2.68 per share	2.96
EQRX EQRx	N/A	N/A	N/A	N/A	$2.40 per share	N/A
SAGE Sage Therapeutics	$41.24M	13.86	N/A	N/A	$7.60 per share	1.20
VERV Verve Therapeutics	$32.33M	30.66	N/A	N/A	$5.83 per share	1.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	$5.75M	$0.28	28.29	14.14	N/A	16.11%	14.27%	9.93%	7/30/2025 (Estimated)
EQRX EQRx	-$169.09M	-$0.55	N/A	∞	N/A	N/A	-20.33%	-19.32%	N/A
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)
VERV Verve Therapeutics	-$198.71M	-$2.11	N/A	N/A	N/A	-303.64%	-35.81%	-27.57%	8/14/2025 (Estimated)

Latest SAGE, EQRX, AUPH, and VERV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	VERV Verve Therapeutics	-$0.71	-$0.35	+$0.36	-$0.35	$7.13 million	$32.98 million
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EQRX EQRx	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.16	5.93	5.26
EQRX EQRx	N/A	18.77	22.60
SAGE Sage Therapeutics	N/A	9.13	9.13
VERV Verve Therapeutics	N/A	9.84	9.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
EQRX EQRx	72.33%
SAGE Sage Therapeutics	99.22%
VERV Verve Therapeutics	97.11%

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	12.20%
EQRX EQRx	18.30%
SAGE Sage Therapeutics	5.50%
VERV Verve Therapeutics	19.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	135.10 million	118.62 million	Optionable
EQRX EQRx	362	487.42 million	398.22 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable
VERV Verve Therapeutics	110	89.14 million	71.40 million	Optionable

SAGE, EQRX, AUPH, and VERV Headlines

Recent News About These Companies

Q2 Earnings Forecast for VERV Issued By Lifesci Capital

June 19 at 7:06 AM | marketbeat.com

Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug

June 19 at 2:26 AM | insidenova.com

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B

June 19 at 2:26 AM | msn.com

Verve Therapeutics (NASDAQ:VERV) Lowered to Hold Rating by William Blair

June 19 at 1:19 AM | americanbankingnews.com

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

June 18 at 11:28 PM | businesswire.com

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

June 18 at 10:35 AM | zacks.com

Verve Therapeutics (NASDAQ:VERV) Receives Neutral Rating from HC Wainwright

June 18 at 8:05 AM | marketbeat.com

Lifesci Capital Reaffirms "Market Perform" Rating for Verve Therapeutics (NASDAQ:VERV)

June 18 at 8:05 AM | marketbeat.com

Verve Therapeutics' (VERV) "Hold" Rating Reiterated at Jefferies Financial Group

June 18 at 8:05 AM | marketbeat.com

Lock In The 81.5% Run - Initiating Verve With A Sell

June 18 at 7:36 AM | seekingalpha.com

Verve Therapeutics (NASDAQ:VERV) Sets New 12-Month High - Here's Why

June 18 at 5:05 AM | marketbeat.com

Canaccord Genuity Group Reiterates Hold Rating for Verve Therapeutics (NASDAQ:VERV)

June 18 at 2:27 AM | americanbankingnews.com

Verve Therapeutics Target of Unusually High Options Trading (NASDAQ:VERV)

June 18 at 1:12 AM | americanbankingnews.com

These Stocks Are Moving the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More

June 17 at 10:41 PM | msn.com

Eli Lilly to Acquire Verve Therapeutics for $1 Billion

June 17 at 5:40 PM | pharmexec.com

Lilly to Buy Gene-Editing Partner Verve for up to $1.3 Billion in Cardiac Care Push

June 17 at 5:40 PM | money.usnews.com

Eli Lilly lands “bargain” deal to acquire Verve Therapeutics for $1.3bn

June 17 at 5:40 PM | finance.yahoo.com

Eli Lilly Co. to buy gene-editing startup Verve to develop cardiac drugs

June 17 at 5:40 PM | msn.com

These Stocks Moved the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More

June 17 at 5:40 PM | msn.com

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly

June 17 at 1:16 PM | zacks.com

Verve Therapeutics Target of Unusually Large Options Trading (NASDAQ:VERV)

June 17 at 1:12 PM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SAGE, EQRX, AUPH, and VERV Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

$7.92 +0.01 (+0.13%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$7.98 +0.07 (+0.82%)

As of 06/18/2025 07:56 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

EQRx NASDAQ:EQRX

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. As of November 9, 2023, EQRx, Inc. operates as a subsidiary of Revolution Medicines, Inc.

Sage Therapeutics NASDAQ:SAGE

$9.13 +0.01 (+0.11%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$9.18 +0.05 (+0.60%)

As of 06/18/2025 07:58 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Verve Therapeutics NASDAQ:VERV

$11.12 -0.26 (-2.28%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$11.15 +0.03 (+0.23%)

As of 06/18/2025 07:59 PM Eastern

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time